Revenues of Arcus Biosciences, Inc. from 30 Sep 2017 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
- Summary
-
Arcus Biosciences, Inc. quarterly and annual Revenues in USD history and change rate from 30 Sep 2017 to 31 Dec 2025.
- Arcus Biosciences, Inc. Revenues for the quarter ending 31 Dec 2025 was $33,000,000, a 27% increase year-over-year.
- Arcus Biosciences, Inc. Revenues for the twelve months ending 31 Dec 2025 was $247,000,000, a 4.3% decline year-over-year.
- Arcus Biosciences, Inc. annual Revenues for 2025 was $247,000,000, a 4.3% decline from 2024.
- Arcus Biosciences, Inc. annual Revenues for 2024 was $258,000,000, a 121% increase from 2023.
- Arcus Biosciences, Inc. annual Revenues for 2023 was $117,000,000, a 4.5% increase from 2022.
- Source SEC data
- View on sec.gov
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Change (%)
Revenues, Annual (USD)
Revenues, YoY Annual Change (%)
Arcus Biosciences, Inc. Quarterly Revenues (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $247,000,000 | $33,000,000 | +$7,000,000 | +27% | 01 Oct 2025 | 31 Dec 2025 | 10-K | 25 Feb 2026 | 2025 | FY |
| Q3 2025 | $240,000,000 | $26,000,000 | -$22,000,000 | -46% | 01 Jul 2025 | 30 Sep 2025 | 10-Q | 28 Oct 2025 | 2025 | Q3 |
| Q2 2025 | $262,000,000 | $160,000,000 | +$121,000,000 | +310% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 06 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $141,000,000 | $28,000,000 | -$117,000,000 | -81% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 06 May 2025 | 2025 | Q1 |
| Q4 2024 | $258,000,000 | $26,000,000 | 01 Oct 2024 | 31 Dec 2024 | 10-K | 25 Feb 2026 | 2025 | FY | ||
| Q3 2024 | $48,000,000 | 01 Jul 2024 | 30 Sep 2024 | 10-Q | 28 Oct 2025 | 2025 | Q3 | |||
| Q2 2024 | $39,000,000 | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 06 Aug 2025 | 2025 | Q2 | |||
| Q1 2024 | $145,000,000 | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 06 May 2025 | 2025 | Q1 | |||
| Q4 2020 | $77,517,000 | $9,487,000 | -$263,000 | -2.7% | 01 Oct 2020 | 31 Dec 2020 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q3 2020 | $77,780,000 | $64,530,000 | +$62,780,000 | +3587% | 01 Jul 2020 | 30 Sep 2020 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q2 2020 | $15,000,000 | $1,750,000 | $0 | 0% | 01 Apr 2020 | 30 Jun 2020 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q1 2020 | $15,000,000 | $1,750,000 | $0 | 0% | 01 Jan 2020 | 31 Mar 2020 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q4 2019 | $15,000,000 | $9,750,000 | +$8,188,000 | +524% | 01 Oct 2019 | 31 Dec 2019 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q3 2019 | $6,812,000 | $1,750,000 | -$2,541,000 | -59% | 01 Jul 2019 | 30 Sep 2019 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q2 2019 | $9,353,000 | $1,750,000 | +$500,000 | +40% | 01 Apr 2019 | 30 Jun 2019 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q1 2019 | $8,853,000 | $1,750,000 | +$500,000 | +40% | 01 Jan 2019 | 31 Mar 2019 | 10-K | 25 Feb 2021 | 2020 | FY |
| Q4 2018 | $8,353,000 | $1,562,000 | +$312,000 | +25% | 01 Oct 2018 | 31 Dec 2018 | 10-K | 05 Mar 2020 | 2019 | FY |
| Q3 2018 | $8,041,000 | $4,291,000 | +$4,128,000 | +2533% | 01 Jul 2018 | 30 Sep 2018 | 10-K | 05 Mar 2020 | 2019 | FY |
| Q2 2018 | $3,913,000 | $1,250,000 | 01 Apr 2018 | 30 Jun 2018 | 10-K | 05 Mar 2020 | 2019 | FY | ||
| Q1 2018 | $1,250,000 | 01 Jan 2018 | 31 Mar 2018 | 10-K | 05 Mar 2020 | 2019 | FY | |||
| Q4 2017 | $1,250,000 | 01 Oct 2017 | 31 Dec 2017 | 10-K | 05 Mar 2019 | 2018 | FY | |||
| Q3 2017 | $163,000 | 01 Jul 2017 | 30 Sep 2017 | 10-K | 05 Mar 2019 | 2018 | FY |
Arcus Biosciences, Inc. Annual Revenues (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $247,000,000 | -$11,000,000 | -4.3% | 01 Jan 2025 | 31 Dec 2025 | 10-K | 25 Feb 2026 | 2025 | FY |
| 2024 | $258,000,000 | +$141,000,000 | +121% | 01 Jan 2024 | 31 Dec 2024 | 10-K | 25 Feb 2026 | 2025 | FY |
| 2023 | $117,000,000 | +$5,000,000 | +4.5% | 01 Jan 2023 | 31 Dec 2023 | 10-K | 25 Feb 2026 | 2025 | FY |
| 2022 | $112,000,000 | 01 Jan 2022 | 31 Dec 2022 | 10-K | 25 Feb 2025 | 2024 | FY | ||
| 2019 | $15,000,000 | +$6,647,000 | +80% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 05 Mar 2020 | 2019 | FY |
| 2018 | $8,353,000 | +$6,940,000 | +491% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 05 Mar 2020 | 2019 | FY |
| 2017 | $1,413,000 | 01 Jan 2017 | 31 Dec 2017 | 10-K | 05 Mar 2019 | 2018 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.